Pevonedistat and Azacitidine in Treating Patients with Refractory or Relapsed Myelodysplastic Syndrome or Myelodysplastic Syndrome / Myeloproliferative Neoplasm Who Fail Primary Therapy

Status: Active

Description

This phase II trial studies how well pevonedistat and azacitidine work in treating patients with myelodysplastic syndrome or myelodysplastic syndrome / myeloproliferative neoplasm that have fails primary therapy and that does not respond to treatment or has come back. Pevonedistat and azacitidine may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Eligibility Criteria

Inclusion Criteria

  • Signed and dated voluntary written informed consent before performance of any study related procedure not part of standard medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care
  • Morphologically confirmed diagnosis of MDS or MDS/MPN in accordance with World Health Organization (WHO) diagnostic criteria
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2
  • Expected survival >= 3 months after consenting
  • Refractory/relapsed disease following DNMTi failure; refractory disease defined as either 1) failure to achieve an objective response after at least 4 cycles of DNMTi therapy, or 2) failure to achieve an objective response with clear progressive disease on bone marrow biopsy after at least 2 cycles of DNMTi therapy; relapsed disease is defined as having progressive disease after achieving an objective response after at least 2 cycles of DNMTi therapy; previous DNMTi therapy may include 5’azacitidine, decitabine, or DNMTi therapy currently in clinical trials (e.g. SGI-110 [guadecitabine], ASTX727 or CC-486); to be considered DNMTi treatment failure, during each prior treatment cycle, patients must have received minimum dosing of: * Decitabine 15 mg/m^2 daily x 5 days, or * 5’azacitidine 50 mg/m^2 IV/SC daily x 5 days, * SGI-110 (guadecitabine) 60 mg/m^2 SC daily x 5 days, or * Oral DNMTi therapy with ASTX727 20/100 mg daily x 5 days, or * Oral DNMTi therapy with CC-486 200 mg daily x 14 days
  • Recovery to =< grade 1 or baseline of any toxicity due to prior systemic treatments, excluding alopecia
  • Patient consent to collection of fresh bone marrow biopsy and aspirate for exploratory research obtained from a procedure performed no more than 28 days prior to initiating treatment on cycle 1, day 1
  • Serum albumin > 2.7 g/dL
  • Total bilirubin =< upper limit of normal (ULN)
  • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2 x ULN
  • Calculated creatinine clearance >= 50 mL/min (per the Cockcroft-Gault formula)
  • Hemoglobin > 8 g/dL (prior red blood cell [RBC] transfusion allowed); patients may be transfused to achieve this value
  • Women of childbearing potential must have a negative serum pregnancy test; and additionally agree to simultaneously use at least 2 methods of effective contraception or abstain from heterosexual intercourse from the time of signing consent, and until 4 months after patient’s last dose of protocol-indicated treatment; periodic abstinence (e.g. calendar, ovulation, symptothermal, postovulation methods for the female partner) and withdrawal are not acceptable methods of contraception; women of child bearing potential (WOCBP) are defined as those not surgically sterile or not post-menopausal; if a female patient has not had a bilateral tubal ligation, a bilateral oophorectomy, or a complete hysterectomy; or has not been amenorrheic for at least 1 year in the absence of an alternative medical cause, then patient will be considered a female of childbearing potential; postmenopausal status in females under 55 years of age should be confirmed with a serum follicle stimulating hormone (FSH) level within laboratory reference range for postmenopausal women
  • Men, even if surgically sterilized (i.e. status post-vasectomy), who are sexually active with WOCBP must agree to follow instructions for effective barrier contraception from the time of signing consent and until 4 months after last dose of protocol-indicated treatment; periodic abstinence (e.g. calendar, ovulation, symptothermal, postovulation methods for the female partner) and withdrawal are not acceptable methods of contraception

Exclusion Criteria

  • Diagnosis of acute myeloid leukemia (i.e. >= 20% peripheral or marrow blasts)
  • Any HSCT within 6 months prior to signing informed consent
  • Any patient who is eligible for HSCT at the time of study screening
  • Clinically significant graft versus host disease (GVHD) or GVHD requiring initiation of treatment or treatment escalation within 21 days, and/or > grade 1 persistent or clinically significant non-hematologic toxicity related to HSCT
  • Any previous treatment with pevonedistat or other NEDD8 inhibitor
  • Treatment with any investigational products within 14 days before the first dose of protocol-indicated treatment
  • Systemic antineoplastic therapy or radiotherapy within 14 days before the first dose of any study drug
  • Major surgery requiring general anesthesia within 14 days before the first dose of any study drug or a scheduled surgery during study period; (placement of a central line or port-a-catheter is acceptable within this time frame and does not exclude the patient)
  • Treatment with clinically significant metabolic CYP3A inducers within 14 days before the first dose of study drug; clinically significant CYP3A inducers are not permitted during the study
  • Prolonged corrected QT (QTc) interval > 500 msec, calculated according to Fridericia's formula
  • Known cardiopulmonary disease defined as having one or more of the following: * Uncontrolled high blood pressure (i.e. systolic > 180 mmHg or diastolic > 95 mmHg); * Cardiomyopathy * Ischemic heart disease; patients with acute coronary syndrome, myocardial infarction, and/or revascularization (e.g. coronary artery bypass graft, stent) within 6 months of first dose of study drug are excluded; patients with a history of ischemic heart disease who have had revascularization greater than 6 months before screening and who are without cardiac symptoms may enroll * Arrhythmia (e.g. history of polymorphic ventricular fibrillation or torsade de pointes); patients with symptomatic atrial fibrillation (Afib) incompletely controlled medically, or controlled by device (e.g. pacemaker) or by ablation are excluded; however, patients with stable, asymptomatic AFib for a period of at least 6 months, whose Afib is controlled with medication, or who have a history of paroxysmal AFib are permitted to enroll * Implantable cardioverter defibrillator * Congestive heart failure (New York Heart Association [NYHA] class III or IV; or class II with a recent decompensation requiring hospitalization or referral to a heart failure clinic within 4 weeks before screening) * Moderate to severe aortic and/or mitral stenosis or other valvulopathy (ongoing); mild regurgitation is not excluded * Pulmonary hypertension
  • Female patients who are both lactating and breastfeeding, who have a positive serum pregnancy test during screening, or who plan to become pregnant while in the trial or within 90 days after receiving protocol-directed treatment
  • Active uncontrolled infection; patients with infection under active treatment and controlled with antibiotics are not excluded
  • Known Childs class B or C hepatic cirrhosis or severe pre-existing hepatic impairment
  • Known hepatitis B surface antigen seropositivity or known or suspected active hepatitis C infection; Note: Patients who have isolated positive hepatitis B core antibody (i.e. in the setting of negative hepatitis B surface antigen and negative hepatitis B surface antibody) must have an undetectable hepatitis B viral load
  • Known human immunodeficiency virus (HIV) seropositivity
  • Any serious concurrent condition that could, in the investigator’s opinion, significantly interfere with completion of study procedures or protocol compliance
  • Female patients who intend to donate eggs (ova) during the course of this study or 4 months after receiving their last dose of study drug(s)
  • Male patients who intend to donate sperm during the course of this study or 4 months after receiving their last dose of study drug(s)

Locations & Contacts

Florida

Miami
University of Miami Miller School of Medicine-Sylvester Cancer Center
Status: Active
Contact: Justin Michael Watts
Email: jxw401@miami.edu

Kansas

Kansas City
University of Kansas Cancer Center
Status: Active
Contact: Barry S. Skikne
Email: bskikne@kumc.edu

New York

New York
Memorial Sloan Kettering Cancer Center
Status: Active
Contact: Virginia M. Klimek
Email: klimekv@mskcc.org
Rochester
University of Rochester
Status: Active
Contact: Jason Harold Mendler
Email: Jason_Mendler@URMC.Rochester.edu

Tennessee

Nashville
Vanderbilt University / Ingram Cancer Center
Status: Active
Contact: Michael Robert Savona
Phone: 615-322-4967

Trial Objectives and Outline

PRIMARY OBJECTIVES:

I. To compare survival of patients treated with a combination of pevonedistat and azacitidine after failure of deoxyribonucleic acid (DNA) methyltransferase inhibitors (DNMTi) to historical survival for patients with relapsed/refractory myelodysplastic syndrome (MDS) or MDS/myeloproliferative neoplasm (MPN) who are ineligible for hematopoietic stem cell transplant (HSCT).

SECONDARY OBJECTIVES:

I. To determine the rate of hematologic improvement (HI) in patients with relapsed/refractory MDS or MDS/MPN treated with pevonedistat and azacitidine after DNMTi failure.

II. To determine the complete remission (CR) and marrow CR rates in patients with relapsed/refractory MDS or MDS/MPN treated with pevonedistat and azacitidine after DNMTi failure.

II. To determine the reduction of bone marrow blasts in patients with relapsed/refractory MDS or MDS/MPN treated with pevonedistat and azacitidine after DNMTi failure.

TERTIARY OBJECTIVES:

I. To correlate the mutation burden in patients with relapsed/refractory MDS or MDS/MPN with response to treatment with pevonedistat and azacitidine.

II. To correlate genomic aberrations with rate of response and survival in relapsed/refractory MDS or MDS/MPN patients treated with pevonedistat and azacitidine.

III. To measure the effect of pevonedistat treatment in combination with azacitidine on quality of life in patients with relapsed/refractory MDS or MDS/MPN.

IV. To define epigenetic biomarkers for pevonedistat use in relapsed/refractory MDS or MDS/MPN.

OUTLINE:

Patients receive azacitidine subcutaneously (SC) or intravenously (IV) over 10-40 minutes on days 1-5 and pevonedistat IV over 60 minutes on days 1, 3, and 5. Courses repeat every 28 days for up to 12 months in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 30 days and then every 3 months for up to 1 year.

Trial Phase & Type

Trial Phase

Phase II

Trial Type

Treatment

Lead Organization

Lead Organization
Vanderbilt University / Ingram Cancer Center

Principal Investigator
Michael Robert Savona

Trial IDs

Primary ID VICC HEM 16146
Secondary IDs NCI-2017-01377
Clinicaltrials.gov ID NCT03238248